Balkrishna Acharya, Sharma Sonam, Dey Tapan, Maity Madhulina, Shukla Sunil, Kumari Ankita, Tomer Meenu, Dev Rishabh, Sinha Sandeep, Varshney Anurag
Drug Discovery and Development Division, Patanjali Research Foundation, Governed by Patanjali Research Foundation Trust, Haridwar, Uttarakhand, India.
Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Haridwar, Uttarakhand, India.
J Inflamm Res. 2025 Apr 18;18:5235-5259. doi: 10.2147/JIR.S505245. eCollection 2025.
Psoriasis is a chronic inflammatory skin disease that occurs among all age groups, irrespective of gender, and consequently it negatively impacts patient's quality of life. Medicines of herbo-mineral origin are being increasingly used for the mitigation of psoriasis, due to the side effects associated with the available treatment options. Present study characterizes the pharmacological efficacy of Psorogrit (PSO) and Divya-Taila (DT) using in vitro and in vivo assays.
Human keratinocyte (HaCaT) cells stimulated with TNF-α or Imiquimod (IMQ) were used to generate the in vitro models of psoriasis. PSO was further evaluated for modulation of mRNA expression, cytokine levels and NF-κB reporter activity. The in vivo anti-psoriatic activity of the orally given PSO and topically applied DT was assessed in mouse models of IMQ-induced psoriasis-like skin lesions and 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear edema. The animals were randomly allocated to the Normal control, Disease control, Clobetasol, PSO and DT groups. Analysis of ear thickness, ear punch weight, spleen weight, histopathology by hematoxylin and eosin (H&E), and () mRNA expression was measured for evaluation of these herbal formulations. Moreover, the phytochemical composition of PSO and DT was evaluated by UHPLC and GC/MS/MS.
Cytosafe concentrations of PSO significantly attenuated IL-8 release as well as mRNA expressions of , , and in TNF-α-induced human skin keratinocytes. PSO was observed to decrease the TNF-α-induced NF-κB reporter activity. Additionally, in IMQ-induced HaCaT cells, PSO reduced the release of IL-17RA and mRNA expression of and . In the in vivo IMQ-induced model, PSO and DT were able to ameliorate the IMQ-induced increase in ear punch weight, relative spleen weight, and histopathological changes in both ear and dorsal back skin. In TPA-induced ear edema model, PSO and DT reduced the increase in ear thickness, ear punch weight, and histopathological lesions. Besides, the phytochemical analysis of PSO and DT revealed the presence of phytometabolites known to have anti-inflammatory activities.
The combinatorial use of Psorogrit and Divya-Taila has the potential to ameliorate clinical and pathological manifestations of psoriasis.
银屑病是一种慢性炎症性皮肤病,可发生于所有年龄组,不分性别,因此对患者的生活质量产生负面影响。由于现有治疗方案存在副作用,草药矿物来源的药物越来越多地用于减轻银屑病症状。本研究通过体外和体内试验对银屑消(PSO)和迪维亚油(DT)的药理作用进行了表征。
用肿瘤坏死因子-α(TNF-α)或咪喹莫特(IMQ)刺激人角质形成细胞(HaCaT),建立银屑病体外模型。进一步评估PSO对mRNA表达、细胞因子水平和核因子-κB(NF-κB)报告基因活性的调节作用。在IMQ诱导的银屑病样皮肤损伤小鼠模型和12-O-十四酰佛波醇-13-乙酸酯(TPA)诱导的耳水肿小鼠模型中,评估口服PSO和局部应用DT的体内抗银屑病活性。将动物随机分为正常对照组、疾病对照组、氯倍他索组、PSO组和DT组。通过测量耳厚度、耳打孔重量、脾脏重量、苏木精和伊红(H&E)染色的组织病理学以及()mRNA表达,对这些草药制剂进行评估。此外,通过超高效液相色谱(UHPLC)和气相色谱/质谱/质谱(GC/MS/MS)对PSO和DT的植物化学成分进行了评估。
PSO的细胞安全浓度显著减弱了TNF-α诱导的人皮肤角质形成细胞中白细胞介素-8(IL-8)的释放以及()、()、()和()的mRNA表达。观察到PSO降低了TNF-α诱导的NF-κB报告基因活性。此外,在IMQ诱导的HaCaT细胞中,PSO减少了IL-17RA的释放以及()和()的mRNA表达。在体内IMQ诱导的模型中,PSO和DT能够改善IMQ诱导的耳打孔重量、相对脾脏重量增加以及耳部和背部皮肤的组织病理学变化。在TPA诱导的耳水肿模型中,PSO和DT减轻了耳厚度、耳打孔重量和组织病理学损伤的增加。此外,PSO和DT的植物化学分析显示存在已知具有抗炎活性的植物代谢产物。
银屑消和迪维亚油联合使用有可能改善银屑病的临床和病理表现。